Table 1: MCL and FL composite lymphomas.

Case numberAgeInvolvementImmunohistochemistry staining  TreatmentFollow-upRef
Gender

166 FWaldeyer ring
Tonsil
Pharyngeal wall
Lingual tonsil
Nasal cavity
MCL: CD5+, CD20+, IgD+, cyclinD1+, Bcl-2+, CD3−
FL: CD2+, CD10+, Bcl-2+, Bcl-6+, CD5−
CorticosteroidPET scan every 3–6 months[2]

2MOcular adnexaNANAPoor prognosis mentioned[3]

384 FSpleenFL: CD20+, CD23+, Bcl-6+, CD5−, CD43−, Bcl-2−
MCL: cyclinD1+, CD5−
Splenectomy
Patient refused additional treatment
9 months after splenectomy, CT scan showed intra-abdominal lymphadenopathy and patient died from unknown cause 13 months later[4]

470 FCervical LN
Inguinal LN
CD20+, CD3−, cyclinD1−
50% of B-cell expressed CD5 (MCL)
30% of B-cell expressed CD10 (FL)
No chemotherapyCT of chest and abdomen showed no evidence of lymphadenopathy or hepatosplenomegaly[5]

565 MInguinal LNFL: CD20+, CD79a+, CD10+, Bcl-2+, CD5−, CD230, cyclinD1−, p27+
MCL: CD20+, CD79a+, CD5+, CD10−, CD23−, cyclinD1+, p27−
Interfollicular areas mostly CD5+ showing distinct cylinD1 staining
SplenectomyMCL caused disease progression into spleen. One year after splenectomy, it achieved stable disease[6]

658 FMesenteric LN
Small bowel
MCL: CD5+, CD20+, CD43+
FL: CD10+, CD20+, p27+
22 cycles of chemotherapy over 2 yearsComplete remission[7]